A novel method to prepare highly encapsulated interferon-α-2b containing liposomes for intramuscular sustained release

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 64, Issue 1, 2006, Pages 9-15

  Yang, Li ^a   Yang, Wenzhan ^b   Bi, Dianzhou ^a   Zeng, Qun ^c  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c Beijing Snowle Biotechnology Limited Corporation   (China)

Author keywords

Film hydration dilution; Interferon 2b; Intramuscular injection; Liposome; Sustained release

Indexed keywords

ALPHA2B INTERFERON; LIPOSOME;

ANIMAL EXPERIMENT; ARTICLE; CIRCULATION; DILUTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MEMBRANE VESICLE; MOUSE; NONHUMAN; SUSTAINED DRUG RELEASE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON ALFA-2B; LIPOSOMES; MICE; MUSCLES; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TIME FACTORS;

EID: 33746556590     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.03.003     Document Type: Article

References (29)

1. Eppstein D.A., and Stewart II W.E. Altered pharmacological properties of liposome-associated human interferon-alpha. J. Virol. 41 (1982) 575-582
2. Karau C., Pteszulat M., and Schmidt P.C. Preparation and stability of interferon-α-containing liposomes. Int. J. Pharm. 128 (1996) 89-98
3. Radwanski E., Perentesis G., Jacobs S., Oden E., Affrime M., Symchowicz S., and Zmpaglione N. Pharmacokinetics of Interferon-α-2b in healthy volunteers. J. Clin. Pharmacol. 27 (1987) 432-435
4. Hermann J., and Stricker S.H. Interferon-γ liposomes: drug binding properties and antiviral in vitro activity. Eur. J. Pharm. Biopharm. 41 (1995) 361-368
5. Diwan M., and Park T.G. Stabilization of recombinant interferon-α by pegylation for encapsulation in PLGA microspheres. Int. J. Pharm. 252 (2003) 111-122
6. Goldbach, Dumont S., Kessler R., Poindron P., and Stamm A. Preparation and characterization of interferon-γ-containing liposomes. Int. J. Pharm. 123 (1995) 33-39
7. Kataoka T., and Kobayashi T. Enhancement of chemotherapeutic effect by entrapping 1,o-darabinofuranosylcytosine in lipid vesicles and its mode of action. Ann. NY Acad. Sci. 308 (1978) 387-394
8. Mayhew E., Papahadjopoulos D., Rustum Y.M., and Chandrakant D. Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside. Ann. NY Acad. Sci. 308 (1978) 371-386
9. Mayhew E., Rustrum Y.M., Szoka F., and Papahadjopoulos D. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. Cancer Treat. Rep. 63 (1979) 1923-1928
10. Jonah M.M., Cerny E.A., and Rahman Y.E. Tissue distribution of EDTA encapsulated within liposomes of varying surface properties. Biochim. Biophys. Acta 401 (1975) 336-348
11. Jullano R.L., Stamp D., and McCullough N. Pharmacokinetics of liposome-encapsulated antitumor drugs and implications for therapy. Ann. NY Acad. Sci. 308 (1978) 411-423
12. Kimelberg H.K., and Atchison M.L. Effects of entrapment in liposomes on the distribution, degradation and effectiveness of methotrexate in vivo. Ann. NY Acad. Sci. 308 (1978) 395-409
13. Papahadjopoulos D. Liposomes as drug carriers. Annu. Rep. Med. Chem. 14 (1979) 250-260
14. Eppstein D.A. Altered pharmacologic properties of liposome-associated human interferon-alpha. II. J. Interferon Res. 2 (1982) 117-125
15. Mauk M.R., and Gamble R.C. Stability of lipid vesicles in tissues of the mouse: a X-ray perturbed angular correlation study. Proc. Natl. Acad. Sci. USA 76 (1979) 765-769
16. McDougall I.R., Dunnick J.K., Goris M.L., and Krlss J.P. In vivo distribution of vesicles loaded with radiopharmaceuticals: a study of different routes of administration. J. Nucl. Med. 16 (1975) 488-491
17. Van Slooten M.L., Boerman O., Romoren K., Kedar E., Crommelin D.J.A., and Storm G. Liposomes as sustained release system for human interferon-α: biopharmaceutical aspects. Biochim. Biophys. Acta 1530 (2001) 134-145
18. Killion J.J., Fan D., Bucana C.D., Frangos D.N., Price J.E., and Fidler I.J. Augmentation of antiproliferative activity of interferon alfa against human bladder tumor cell lines by encapsulation of interferon alfa within liposomes. J. Natl. Cancer Inst. 81 (1989) 1387-1392
19. Lambros M.P., Abbas S.A., Dunn S.T., Raja T., and Pento T. Targeting hepatocytes with liposomal interferon-alpha: effect on metallothionein gene induction. Res. Commun. Mol. Pathol. Pharmacol. 112 (2002) 50-58
20. Deborah A., Eppstein D.A., Marsh Y.V., Pas V.D.M., Felgner P.L., and Schreiber A.B. Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor. Proc. Natl. Acad. Sci. USA 82 (1985) 3688-3692
21. Ishihara H., Hara T., Aramakj Y., Tsuchiya S., and Hosol K. Preparation of asialofetuin-labeled liposomes with encapsulated human interferon-γ and their uptake by isolated rat hepatocytes. Pharm. Res. 7 (1990) 542-554
22. Weiner N., Williams N., Birch G., Ramachandran C., Shipman C., and Flynn G. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob. Agents Chemother. 33 (1989) 1217-1221
23. Egbaria K., Ramacjamdran C., Kittayandond D., and Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob. Agent Chemother. 34 1 (1990) 107-110
24. Hanley D.F., Wiranowska-Stewart W.E., and Stewart H. Pharmacology of interferons. I. Pharmocologic distinctions between human leukocyte and fibroblast interferons. Int. Immunopharmacol. 1 (1979) 219-226
25. Oussoren C., Storm G., Crommelin D.J.A., and Senior J.H. Liposomes for local sustained drug release. In: Senior J.H., and Radomsky M. (Eds). Sustained-Release Injectable Products (2000), Interpharm Press, Denver, Colorado, USA 145-157
26. Allen T.M., Hansen C.B., and Guo L.S.S. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim. Biophys. Acta 1150 (1993) 9-16
27. Patel H.M. Fate of liposomes in the lymphatics. In: Gregoriadis G. (Ed). Liposomes as Drug Carriers (1988), John Wiley & Sons, Ltd, New York, USA 51-61
28. Tümer A., Kirby C., Senior J., and Gregoriadis G. Fate of cholesterol-rich liposomes after subcutaneous injection into rats. Biochim. Biophys. Acta 760 (1983) 119-125
29. Oussoren C., Zuidema J., Crommelin D.J.A., and Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta 7 (1997) 227-240